Thomas Weisel maintains First Horizon at outperform

First Horizon Pharmaceutical Corp. was maintained at outperform with a $29 price target by Thomas Weisel Partners analyst Donald B. Ellis after the company reported revenue and profit growth in the third quarter. Earnings per share of $0.26 met the Thomas Weisel estimate, revenues grew to $58.7 million, compared to $41.6 million in the third quarter of 2004, and sales of cardiology products increased 61.5% to $43.8 million. Shares of the Alpharetta, Ga.-based pharmaceutical company were down $2.86, or 16.22%, at $14.77 on volume of 6,887,293 shares versus the three-month running average of 418,971 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.